Actively Recruiting

All Genders
Healthy Volunteers
ID06725173

Genetic Associations of Ocular Cancers

Led by University of Washington · Updated on 2026-03-18

100

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

Sponsors

U

University of Washington

Lead Sponsor

N

National Eye Institute (NEI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying patients with ocular cancers and secondary cancers linked to mutations in the RB1 gene. This observational study aims to gain a detailed understanding of how genetic changes in RB1 relate to the development and spread of these cancers. By exploring the relationship between genetic information and disease traits, the study seeks to provide valuable insights into this cancer syndrome. All participants will undergo targeted long-read sequencing to analyze the genetic and epigenetic features of the RB1 gene. This advanced genetic testing helps to identify and understand the specific mutations involved. The study focuses on patients who have retinoblastoma caused by RB1 mutations or who show typical signs of retinoblastoma while awaiting genetic confirmation. Participants will provide consent and donate saliva or blood samples for genetic analysis. Researchers will perform detailed genetic and epigenetic profiling over a five-year period to understand the RB1 gene's role in these cancers. The study includes patients with various forms of retinoblastoma, including bilateral, unilateral, extraocular, and recurrent types, and involves no treatment interventions. Participants' involvement includes genetic testing and follow-up for outcome measurements.

CONDITIONS

Brief Title

Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with molecularly proven retinoblastoma due to RB1 or a typical clinical retinoblastoma phenotype with genetic screening pending
  • Able to give consent or have a parent or guardian able to give consent
Not Eligible

You will not qualify if you...

  • Patients unable or unwilling to undertake consent or clinical testing
  • Patients unwilling to donate a saliva or blood sample to establish the genetic cause of their condition

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 5 years

Participants undergo targeted long-read sequencing to analyze genomic and epigenomic signatures of the RB1 gene.

1 to 2 visits depending on genetic testing procedures

Long-term Monitoring

Duration - Up to 5 years

Participants are observed to correlate RB1 mutations with ocular tumors and metastasis over time.

Periodic visits during the 5-year follow-up

Trial Site Locations

Total: 1 location

1

University of Washington

Seattle, Washington, United States, 98109

Actively Recruiting

Loading map...

Research Team

D

Debarshi Mustafi, MD PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Three Cycles of Adjuvant Chemotherapy for Patients With High...

Retinoblastoma

Actively Recruiting

1 location

Prediction of the Response Using Dynamic Contrast-enhanced M...

Retinoblastoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Prognostic importance of direct assignment of parent of origin via long-read genome and epigenome sequencing in retinoblastoma.

Andrew W Stacey, Kenji Nakamichi, Jennifer Huey...

https://pubmed.ncbi.nlm.nih.gov/39724000

Targeted long-read sequencing allows for rapid identification of pathogenic disease-causing variants in retinoblastoma.

Kenji Nakamichi, Andrew Stacey, Debarshi Mustafi

https://pubmed.ncbi.nlm.nih.gov/36325802